Summit Therapeutics' shares dropped 36% after ivonescimab data showed no significant survival benefit. Click to read if SMMT ...

Many investors are withdrawing their money from the stock market right now, but those focused on the long term know to hold ...

Enfortumab vedotin plus pembrolizumab followed by surgery showed high complete response rates in advanced urothelial cancer.

While Akeso (AKESF) and Summit Therapeutics’ (SMMT) ivonescimab, a rival to Merck’s (MRK) Keytruda, won approval in China this week, the data on patient survival did not meet analyst expectations, ...

Andrew Trench’s life turned upside down by the shocking news that he has stage four oesophageal cancer. After his medical costs were declined by his insurer, he has been blown away by the kindness of ...